August 2013
Reactions Weekly;8/24/2013, Issue 1466, p24
An abstract of the article "Infliximab induction therapy alone for ulcerative colitis does not result in long term remission," by A. J. Brooks and colleagues is presented.


Related Articles

  • Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.  // Inflammatory Bowel Disease Monitor;2012, Vol. 12 Issue 3, p122 

    The article presents a review of a study which investigates the association between infliximab for early mucosal healing and improved long-term clinical outcomes of colectomy in ulcerative colitis. It examines the colectomy outcomes, symptomatic remission, corticosteroid treatment, and sustained...

  • Treatment of inflammatory bowel disease: A review of medical therapy. Kozuch, Patricia L.; Hanauer, Stephen B.; Maaser, Christian // World Journal of Gastroenterology;1/21/2008, Vol. 14 Issue 3, p354 

    Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract. While a cure remains elusive, both can be treated with medications that induce and maintain remission. With the recent advent of therapies that inhibit tumor necrosis factor (TNF)...

  • Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Eun Hye Kim; Duk Hwan Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon // Gut & Liver;Sep2015, Vol. 9 Issue 5, p601 

    Background/Aims: In patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission. Here, we aimed to compare the efficacy of cyclosporine and infliximab. Methods: Between January 1995 and May 2012, the...

  • Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Laharie, D. // Inflammatory Bowel Disease Monitor;2013, Vol. 13 Issue 3, p121 

    A review of the article "Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomized controlled trial," by D. Laharie and colleagues, which appeared in the 2012 issue of "Groupe d'Etudes Thérapeutiques des...

  • Infliximab Therapy for Ulcerative Colitis: Many Unanswered Questions. Present, Daniel H. // American Journal of Gastroenterology;Aug2001, Vol. 96 Issue 8, p2294 

    Introduces the article "Infliximab for Refractory Ulcerative Colitis," by William Y. Chey, Ayub Hussain, Charlotte Ryan, Gregory D. Potter and Ashok Shah.

  • Maintenance infliximab not value for money.  // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p13 

    The article discusses a study on the cost effectiveness of episodic infliximab therapy versus maintenance infliximab therapy and standard treatment in ulcerative colitis by S.H. Odes and colleagues, published in the May 19, 2012 issue of "Digestive Week 2012."

  • Infliximab rescue therapy after cyclosporin failure in steroidrefractory ulcerative colitis.  // Inflammatory Bowel Disease Monitor;Apr2009, Vol. 10 Issue 2, p65 

    The article discusses the use of infliximab as a rescue therapy for patients with active ulcerative colitis who have failed on steroids and cyclosporine.

  • Etanercept/infliximab.  // Reactions Weekly;6/22/2013, Issue 1458, p22 

    The article describes the case of a woman in her sixties who developed ulcerative colitis (UC) while receiving anti-tumour necrosis factor (anti-TNF) therapy with infliximab and etanercept for rheumatoid arthritis.

  • Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis. Jürgens, Matthias; Laubender, Rüdiger P; Hartl, Franziska; Weidinger, Maria; Seiderer, Julia; Wagner, Johanna; Wetzke, Martin; Beigel, Florian; Pfennig, Simone; Stallhofer, Johannes; Schnitzler, Fabian; Tillack, Cornelia; Lohse, Peter; Göke, Burkhard; Glas, Jürgen; Ochsenkühn, Thomas; Brand, Stephan // American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1811 

    OBJECTIVES:We analyzed the efficacy and safety of the antitumor necrosis factor-α antibody infliximab (IFX) for induction therapy in patients with moderate-to-severe ulcerative colitis (UC) in a large single-center cohort.METHODS:A total of 90 UC patients treated with IFX for 14 weeks were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics